# Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

> **NCT02592356** · NA · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Differentiated Thyroid Gland Carcinoma
- Malignant Adrenal Gland Pheochromocytoma
- Malignant Paraganglioma
- Thyroid Gland Medullary Carcinoma

## Interventions

- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Dual X-ray Absorptiometry
- **PROCEDURE:** Physical Examination
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Cabozantinib
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02592356
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-16
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592356, "Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02592356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*